NO313657B1 - Terapautisk preparat for inhalering, fremgangsmåte for fremstilling av dette, anvendelse av en forsterker, ogtörrpulverinhalator - Google Patents

Terapautisk preparat for inhalering, fremgangsmåte for fremstilling av dette, anvendelse av en forsterker, ogtörrpulverinhalator Download PDF

Info

Publication number: NO313657B1
Authority: NO; Norway
Prior art keywords: insulin; therapeutic preparation; particles; absorption; preparation according
Prior art date: 1993-06-24

Application number

NO19955226A

Other languages

English (en)

Norwegian (no)

Other versions

NO955226L (no

NO955226D0 (no

Inventor

Kjell Goeran Erik Baeckstroem

Carl Magnus Olof Dahlbaeck

Peter Edman

Ann Charlotte Birgit Johansson

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-24

Filing date

1995-12-21

Publication date

2002-11-11

1993-06-24 Priority claimed from SE9302198A external-priority patent/SE9302198D0/xx

1994-02-04 Priority claimed from SE9400370A external-priority patent/SE9400370L/xx

1995-12-21 Application filed by Astra Ab filed Critical Astra Ab

1995-12-21 Publication of NO955226D0 publication Critical patent/NO955226D0/no

1996-02-15 Publication of NO955226L publication Critical patent/NO955226L/no

2002-11-11 Publication of NO313657B1 publication Critical patent/NO313657B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 98
230000001225 therapeutic effect Effects 0.000 title claims abstract description 66
238000000034 method Methods 0.000 title claims description 29
229940112141 dry powder inhaler Drugs 0.000 title claims description 11
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 346
102000004877 Insulin Human genes 0.000 claims abstract description 175
108090001061 Insulin Proteins 0.000 claims abstract description 175
229940125396 insulin Drugs 0.000 claims abstract description 172
239000000843 powder Substances 0.000 claims abstract description 64
238000010521 absorption reaction Methods 0.000 claims abstract description 51
239000000126 substance Substances 0.000 claims abstract description 41
210000002345 respiratory system Anatomy 0.000 claims abstract description 37
239000002245 particle Substances 0.000 claims description 56
239000003623 enhancer Substances 0.000 claims description 54
150000001875 compounds Chemical class 0.000 claims description 44
239000000203 mixture Substances 0.000 claims description 37
239000003937 drug carrier Substances 0.000 claims description 16
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 15
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 13
239000000654 additive Substances 0.000 claims description 13
150000003904 phospholipids Chemical class 0.000 claims description 13
239000003833 bile salt Substances 0.000 claims description 11
230000002685 pulmonary effect Effects 0.000 claims description 11
239000004094 surface-active agent Substances 0.000 claims description 11
210000002919 epithelial cell Anatomy 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
230000000996 additive effect Effects 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
239000011362 coarse particle Substances 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
-1 alkyl glycoside Chemical class 0.000 claims description 7
206010012601 diabetes mellitus Diseases 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 7
230000001851 biosynthetic effect Effects 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930182470 glycoside Natural products 0.000 claims description 6
229920000858 Cyclodextrin Polymers 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
229930195725 Mannitol Natural products 0.000 claims description 5
238000001704 evaporation Methods 0.000 claims description 5
230000008020 evaporation Effects 0.000 claims description 5
150000004665 fatty acids Chemical class 0.000 claims description 5
239000000594 mannitol Substances 0.000 claims description 5
235000010355 mannitol Nutrition 0.000 claims description 5
239000011164 primary particle Substances 0.000 claims description 5
210000005166 vasculature Anatomy 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
239000003945 anionic surfactant Substances 0.000 claims description 3
238000007580 dry-mixing Methods 0.000 claims description 3
238000000227 grinding Methods 0.000 claims description 3
239000000832 lactitol Substances 0.000 claims description 3
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
235000010448 lactitol Nutrition 0.000 claims description 3
229960003451 lactitol Drugs 0.000 claims description 3
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
239000000845 maltitol Substances 0.000 claims description 3
229940035436 maltitol Drugs 0.000 claims description 3
235000010449 maltitol Nutrition 0.000 claims description 3
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
230000009885 systemic effect Effects 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 2
108010007979 Glycocholic Acid Proteins 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
229920005862 polyol Polymers 0.000 claims description 2
150000003077 polyols Chemical class 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
150000005846 sugar alcohols Chemical class 0.000 claims description 2
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 2
238000011282 treatment Methods 0.000 claims description 2
229940014499 ursodeoxycholate Drugs 0.000 claims description 2
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 2
238000010422 painting Methods 0.000 claims 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 32
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
239000008103 glucose Substances 0.000 description 16
239000008280 blood Substances 0.000 description 15
210000004369 blood Anatomy 0.000 description 15
238000009472 formulation Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
210000004072 lung Anatomy 0.000 description 10
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
241000282472 Canis lupus familiaris Species 0.000 description 7
239000000243 solution Substances 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 5
230000035699 permeability Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000010410 layer Substances 0.000 description 4
229960001855 mannitol Drugs 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
239000011701 zinc Substances 0.000 description 4
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
239000013553 cell monolayer Substances 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229940032147 starch Drugs 0.000 description 3
230000001839 systemic circulation Effects 0.000 description 3
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
230000008021 deposition Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
231100000037 inhalation toxicity test Toxicity 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229940074410 trehalose Drugs 0.000 description 2
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
229960004949 glycyrrhizic acid Drugs 0.000 description 1
235000019410 glycyrrhizin Nutrition 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
235000010299 hexamethylene tetramine Nutrition 0.000 description 1
239000004312 hexamethylene tetramine Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000010120 metabolic dysregulation Effects 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000004682 mucosal barrier function Effects 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
230000004537 potential cytotoxicity Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
229940082004 sodium laurate Drugs 0.000 description 1
229940045845 sodium myristate Drugs 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
XBYKLNAHPCSCOD-UHFFFAOYSA-M sodium;2-hydroxy-5-methoxybenzoate Chemical compound [Na+].COC1=CC=C(O)C(C([O-])=O)=C1 XBYKLNAHPCSCOD-UHFFFAOYSA-M 0.000 description 1
JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

NO19955226A 1993-06-24 1995-12-21 Terapautisk preparat for inhalering, fremgangsmåte for fremstilling av dette, anvendelse av en forsterker, ogtörrpulverinhalator NO313657B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9302198A SE9302198D0 (sv)	1993-06-24	1993-06-24	Powder preparation for inhalation
SE9400370A SE9400370L (sv)	1994-02-04	1994-02-04	Terapeutisk komposition för inhalation
PCT/SE1994/000633 WO1995000127A1 (en)	1993-06-24	1994-06-23	Therapeutic preparation for inhalation

Publications (3)

Publication Number	Publication Date
NO955226D0 NO955226D0 (no)	1995-12-21
NO955226L NO955226L (no)	1996-02-15
NO313657B1 true NO313657B1 (no)	2002-11-11

Family

ID=26661778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19955226A NO313657B1 (no)	1993-06-24	1995-12-21	Terapautisk preparat for inhalering, fremgangsmåte for fremstilling av dette, anvendelse av en forsterker, ogtörrpulverinhalator

Country Status (32)

Country	Link
US (3)	US5518998C1 (fi)
EP (1)	EP0706382B1 (fi)
JP (2)	JP3874789B2 (fi)
KR (1)	KR100372673B1 (fi)
CN (1)	CN1110301C (fi)
AT (1)	ATE183920T1 (fi)
AU (1)	AU692780B2 (fi)
BR (1)	BR9406907A (fi)
CA (1)	CA2166108C (fi)
CZ (1)	CZ287314B6 (fi)
DE (1)	DE69420412T2 (fi)
DK (1)	DK0706382T3 (fi)
EE (1)	EE03221B1 (fi)
EG (1)	EG20599A (fi)
ES (1)	ES2138087T3 (fi)
FI (1)	FI111688B (fi)
GR (1)	GR3031974T3 (fi)
HK (1)	HK1009584A1 (fi)
HU (1)	HU228129B1 (fi)
IL (1)	IL110084A (fi)
IS (1)	IS1768B (fi)
MX (1)	MX9404761A (fi)
MY (1)	MY112098A (fi)
NO (1)	NO313657B1 (fi)
NZ (1)	NZ268137A (fi)
PL (1)	PL178403B1 (fi)
RU (1)	RU2148398C1 (fi)
SA (1)	SA94150030B1 (fi)
SK (1)	SK283145B6 (fi)
TW (1)	TW402506B (fi)
UA (1)	UA49794C2 (fi)
WO (1)	WO1995000127A1 (fi)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6645504B1 (en)	1987-06-24	2003-11-11	Autoimmune Inc.	Bystander suppression of type I diabetes by oral administration of glucagon
US5645820A (en) *	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en)	1992-07-08	2003-01-21	Inhale Therapeutic Systems, Inc.	Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
WO1994007514A1 (en)	1992-09-29	1994-04-14	Inhale Therapeutic Systems	Pulmonary delivery of active fragments of parathyroid hormone
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US7448375B2 (en) *	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
EP1607086A1 (en) *	1993-01-29	2005-12-21	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
US6632456B1 (en) *	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
GB9322014D0 (en)	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
CZ295827B6 (cs) *	1994-03-07	2005-11-16	Nektar Therapeutics	Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6586006B2 (en)	1994-08-04	2003-07-01	Elan Drug Delivery Limited	Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
EE9700138A (et)	1994-12-22	1997-12-15	Astra Aktiebolag	Aerosoolravimvormid
CA2206657C (en) *	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en)	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
GB9508691D0 (en) *	1995-04-28	1995-06-14	Pafra Ltd	Stable compositions
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
US5669973A (en) *	1995-06-06	1997-09-23	David Sarnoff Research Center, Inc.	Apparatus for electrostatically depositing and retaining materials upon a substrate
US5714007A (en)	1995-06-06	1998-02-03	David Sarnoff Research Center, Inc.	Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
US5654007A (en) *	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
GB9515182D0 (en) *	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US5642727A (en) *	1995-07-25	1997-07-01	David Sarnoff Research Center, Inc.	Inhaler apparatus using a tribo-electric charging technique
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
USRE37053E1 (en)	1996-05-24	2001-02-13	Massachusetts Institute Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) *	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en)	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
US5855913A (en) *	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6652837B1 (en)	1996-05-24	2003-11-25	Massachusetts Institute Of Technology	Preparation of novel particles for inhalation
US6503480B1 (en)	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) *	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US5857456A (en) *	1996-06-10	1999-01-12	Sarnoff Corporation	Inhaler apparatus with an electronic means for enhanced release of dry powders
US5871010A (en) *	1996-06-10	1999-02-16	Sarnoff Corporation	Inhaler apparatus with modified surfaces for enhanced release of dry powders
US20030203036A1 (en) *	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6043214A (en) *	1997-03-20	2000-03-28	Novo Nordisk A/S	Method for producing powder formulation comprising an insulin
US6310038B1 (en)	1997-03-20	2001-10-30	Novo Nordisk A/S	Pulmonary insulin crystals
CO4750643A1 (es) *	1997-06-13	1999-03-31	Lilly Co Eli	Formulacion estable de la insulina que contiene l-arginina y protamina
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) *	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US20010053761A1 (en) *	1998-01-08	2001-12-20	Dimarchi Richard Dennis	Method for administering aspb28-human insulin
US7070799B1 (en) *	1998-02-10	2006-07-04	Generex Pharmaceuticals, Inc.	Method for administering insulin to the buccal region
US6221378B1 (en)	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6149774A (en)	1998-06-10	2000-11-21	Delsys Pharmaceutical Corporation	AC waveforms biasing for bead manipulating chucks
US6451349B1 (en)	1998-08-19	2002-09-17	Quadrant Healthcare (Uk) Limited	Spray-drying process for the preparation of microparticles
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US20040214747A1 (en) *	1999-01-06	2004-10-28	Dimarchi Richard Dennis	Method for administering monomeric insulin
AU2879100A (en) *	1999-02-12	2000-08-29	Miles A. Libbey Iii	Formulation and system for intra-oral delivery of pharmaceutical agents
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US6350432B1 (en)	1999-03-19	2002-02-26	Generex Pharmaceuticals Incorporated	Pressurized container having an aerosolized pharmaceutical composition
US6923979B2 (en)	1999-04-27	2005-08-02	Microdose Technologies, Inc.	Method for depositing particles onto a substrate using an alternating electric field
US6485706B1 (en)	1999-06-04	2002-11-26	Delrx Pharmaceutical Corp.	Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US7169889B1 (en) *	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6858199B1 (en)	2000-06-09	2005-02-22	Advanced Inhalation Research, Inc.	High efficient delivery of a large therapeutic mass aerosol
DK1808438T3 (da) *	1999-06-29	2014-10-27	Mannkind Corp	Rensning og stabilisering af peptid og proteiner i lægemidler
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
WO2001013891A2 (en) *	1999-08-25	2001-03-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
WO2001051030A1 (en) *	2000-01-10	2001-07-19	Dura Pharmaceuticals, Inc.	Pharmaceutical formulation and method for pulmonary and oral delivery
GB0004827D0 (en) *	2000-02-29	2000-04-19	Quadrant Holdings Cambridge	Compositions
JP2001240558A (ja) *	2000-02-29	2001-09-04	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en)	2000-05-10	2007-12-01	Alliance Pharma	Phospholipid-based powders for drug delivery
GB0011807D0 (en) *	2000-05-16	2000-07-05	Quadrant Holdings Cambridge	Formulation for inhalation
US7575761B2 (en) *	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
US6444619B1 (en) *	2000-09-28	2002-09-03	Rohm And Haas Company	Delivery system for cyclopropenes
IL145476A (en)	2000-09-29	2006-07-05	Rohm & Haas	Cyclopropene release systems that require less water
US6953540B2 (en)	2000-09-29	2005-10-11	Rohm And Haas Company	Continuous process for the preparation of encapsulated cyclopropenes
IT1319201B1 (it) *	2000-10-12	2003-09-26	Nicox Sa	Farmaci per il diabete.
DE60137452D1 (de) *	2000-11-29	2009-03-05	Itoham Foods Inc	Pulverzubereitungen und verfahren zu ihrer herstellung
EP2292212A3 (en) *	2000-11-30	2012-08-08	Vectura Limited	Method of making particles for use in a pharmaceutical composition
PT2283817T (pt)	2000-11-30	2016-08-22	Vectura Ltd	Método de fabrico de partículas para utilização numa composição farmacêutica
CN1406131A (zh) *	2000-12-25	2003-03-26	株式会社资生堂	活化交感神经的香料组合物
CA2433335C (en) *	2000-12-29	2010-04-20	Advanced Inhalation Research, Inc.	Particles for inhalation having sustained release properties
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
US6867183B2 (en) *	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
IL158192A0 (en) *	2001-05-04	2004-03-28	Pfizer Prod Inc	Method of preventing type 2 diabetes with aerosolized insulin
US6713452B2 (en)	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) *	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) *	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) *	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) *	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) *	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
GB0114033D0 (en) *	2001-06-09	2001-08-01	Innovata Biomed Ltd	Process
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US6770625B2 (en)	2001-09-07	2004-08-03	Nobex Corporation	Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) *	2001-09-07	2007-01-23	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) *	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) *	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en)	2001-09-07	2005-07-05	Nobex Corporation	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) *	2001-09-07	2006-04-18	Nobex Corporation	Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
KR100951750B1 (ko)	2001-11-01	2010-04-09	노바르티스 아게	분무 건조 방법 및 그 조성물
AU2002352836B2 (en)	2001-11-20	2005-09-29	Alkermes, Inc.	Improved particulate compositions for pulmonary delivery
WO2003043603A1 (en) *	2001-11-20	2003-05-30	Advanced Inhalation Research, Inc.	Particulate compositions for improving solubility of poorly soluble agents
ES2364636T3 (es) *	2001-12-19	2011-09-08	Novartis Ag	Administración pulmonar de aminoglucósidos.
AU2003220125B2 (en)	2002-03-20	2006-06-15	Mannkind Corporation	Inhalation apparatus
US7582284B2 (en) *	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
AU2003226603A1 (en) *	2002-04-19	2003-11-03	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
GB0216562D0 (en) *	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
US7601688B2 (en) *	2002-06-13	2009-10-13	Biocon Limited	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
CN1694689A (zh) *	2002-09-30	2005-11-09	阿库斯菲尔公司	供吸入的缓释多孔微粒
WO2004037843A2 (en) *	2002-10-25	2004-05-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) *	2002-12-19	2005-11-08	Acusphere, Inc.	Methods and apparatus for making particles using spray dryer and in-line jet mill
CN1311868C (zh) *	2003-06-10	2007-04-25	上海兴康医药研究开发有限公司	一种胰岛素干粉吸入剂的制备方法
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
PT1660047E (pt) *	2003-08-13	2014-02-27	Biocon Ltd	Formulação de dosagem sólida de sais de ácidos gordos em micropartículas para agentes terapêuticos
ES2362038T3 (es) *	2003-09-02	2011-06-27	Norton Healthcare Limited	Procedimiento para preparar un medicamento.
WO2005025506A2 (en) *	2003-09-10	2005-03-24	Map Pharmaceuticals, Inc.	Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
CA2552707C (en) *	2004-01-12	2018-03-27	Mannkind Corporation	A method of reducing serum proinsulin levels in type 2 diabetics
US20080248999A1 (en) *	2007-04-04	2008-10-09	Biodel Inc.	Amylin formulations
US20080090753A1 (en) *	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US7279457B2 (en) *	2004-03-12	2007-10-09	Biodel, Inc.	Rapid acting drug delivery compositions
WO2005092301A1 (en) *	2004-03-26	2005-10-06	Universita' Degli Studi Di Parma	Insulin highly respirable microparticles
NZ550320A (en) *	2004-04-15	2010-02-26	Chiasma Inc	Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
DK3520779T3 (da)	2004-04-23	2022-03-21	Cydex Pharmaceuticals Inc	DPI formulering indeholdende sulfoalkylethercyclodextrin
KR101309770B1 (ko)	2004-07-19	2013-09-30	바이오콘 리미티드	인슐린―올리고머 접합체，제형 및 이들의 용도
DE602005024413D1 (de)	2004-08-20	2010-12-09	Mannkind Corp	Katalyse der diketopiperazinsynthese
EP2322180B1 (en)	2004-08-23	2015-05-27	MannKind Corporation	Diketopiperazine salts for drug delivery
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
CN102614131A (zh)	2005-09-14	2012-08-01	曼金德公司	以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) *	2005-09-29	2007-04-19	Biodel, Inc.	Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
WO2007043059A1 (en) *	2005-10-13	2007-04-19	Biocon Limited	Process for the preparation of insulin conjugates.
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2005338631B2 (en) *	2005-11-30	2011-12-01	Generex Pharmaceuticals Inc.	Orally absorbed pharmaceutical formulation and method of administration
US20070178166A1 (en) *	2005-12-15	2007-08-02	Acusphere, Inc.	Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
TWI299993B (en) *	2005-12-15	2008-08-21	Dev Center Biotechnology	Aqueous inhalation pharmaceutical composition
US20070148211A1 (en) *	2005-12-15	2007-06-28	Acusphere, Inc.	Processes for making particle-based pharmaceutical formulations for oral administration
BRPI0707991B8 (pt)	2006-02-22	2021-05-25	Mannkind Corp	métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
EP1991532B1 (en)	2006-02-24	2017-01-11	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
KR101191322B1 (ko)	2006-04-07	2012-10-16	메리온 리서치 Ⅲ 리미티드	증진제를 함유하는 고형 경구용 투여 제형
AU2007238114B2 (en) *	2006-04-12	2010-10-14	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
EP2120875B1 (en)	2007-02-11	2018-07-11	Map Pharmaceuticals Inc.	Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
KR100785656B1 (ko)	2007-05-14	2007-12-17	재단법인서울대학교산학협력재단	소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
KR101234540B1 (ko) *	2007-10-16	2013-02-19	바이오콘 리미티드	경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
EP2954893A1 (en)	2007-10-24	2015-12-16	MannKind Corporation	An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
ES2394589T3 (es)	2007-12-14	2013-02-04	Aerodesigns, Inc	Suministro de productos alimenticios transformables en aerosol
US20090271021A1 (en) *	2008-04-28	2009-10-29	Popp Shane M	Execution system for the monitoring and execution of insulin manufacture
CA2723558A1 (en) *	2008-05-07	2009-11-12	Merrion Research Iii Limited	Compositions of gnrh related compounds and processes of preparation
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
IL313823A (en)	2008-06-13	2024-08-01	Mannkind Corp	A dry powder inhaler and system for drug delivery
AU2009259883B2 (en)	2008-06-20	2015-02-05	Mannkind Corporation	An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
PL2343982T3 (pl)	2008-09-17	2017-10-31	Chiasma Inc	Kompozycje farmaceutyczne i związane z nimi sposoby dostarczania
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
JP5918539B2 (ja)	2009-01-08	2016-05-18	マンカインドコーポレイション	Ｇｌｐ−１を用いる高血糖症の治療方法
PT2565193E (pt)	2009-01-23	2014-06-05	Rigel Pharmaceuticals Inc	Composições e métodos para a inibição da via jak
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
CA2754595C (en)	2009-03-11	2017-06-27	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
US20100310660A1 (en) *	2009-06-08	2010-12-09	Taipei Medical University	Dry powder microparticles for pulmonary delivery
KR20190090092A (ko)	2009-06-12	2019-07-31	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en)	2009-11-03	2012-09-12	MannKind Corporation	An apparatus and method for simulating inhalation efforts
WO2011092690A1 (en)	2010-01-26	2011-08-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd	Compositions and methods for prevention and treatment of pulmonary hypertension
US9089484B2 (en)	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20130117755A (ko)	2010-06-21	2013-10-28	맨카인드 코포레이션	건조 분말 약물 운반 시스템 및 방법
US8802114B2 (en)	2011-01-07	2014-08-12	Merrion Research Iii Limited	Pharmaceutical compositions of iron for oral administration
MX353285B (es)	2011-04-01	2018-01-05	Mannkind Corp	Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
JP6231548B2 (ja)	2012-03-23	2017-11-15	マテオンセラピューティクス，インコーポレイテッド	カテプシンの阻害のための組成物および方法
BR112015000529B1 (pt)	2012-07-12	2022-01-11	Mannkind Corporation	Inalador de pó seco
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
KR102391750B1 (ko)	2013-03-15	2022-04-28	맨카인드 코포레이션	미세결정성 디케토피페라진 조성물 및 방법
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
CA2910766C (en)	2013-04-30	2020-12-15	Otitopic Inc.	Dry powder formulations and methods of use
BR112016000937A8 (pt)	2013-07-18	2021-06-22	Mannkind Corp	formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
EP3107548B8 (en)	2014-02-20	2022-07-20	Otitopic Inc.	Dry powder formulations for inhalation
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
WO2016120378A1 (en)	2015-01-29	2016-08-04	Novo Nordisk A/S	Tablets comprising glp-1 agonist and enteric coating
WO2016126830A1 (en)	2015-02-03	2016-08-11	Chiasma Inc.	Method of treating diseases
WO2017193110A1 (en) *	2016-05-06	2017-11-09	Stites Adam	Cannabinoid compositions for sublingual spray nebulizer
WO2019201712A1 (en) *	2018-04-16	2019-10-24	Ioulia Tseti	A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
WO2020092845A1 (en)	2018-11-01	2020-05-07	Rigel Pharmaceuticals, Inc.	Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en)	2019-05-29	2020-12-03	Rigel Pharmaceuticals, Inc.	Method of preventing and treating thrombosis
MX2022001596A (es)	2019-08-08	2022-03-11	Rigel Pharmaceuticals Inc	Compuestos y metodos para tratar sindrome de liberacion de citocinas.
EP4013420B1 (en)	2019-08-14	2023-11-01	Rigel Pharmaceuticals, Inc.	Method of blocking or ameliorating cytokine release syndrome
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
CN119301121A (zh)	2022-03-23	2025-01-10	里格尔药品股份有限公司	作为irak抑制剂的嘧啶-2-基-吡唑化合物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE556587A (fi)	1957-01-31	1957-04-11
GB1527605A (en) *	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
JPS6034925B2 (ja)	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
JPS5795920A (en)	1980-12-04	1982-06-15	Teijin Ltd	Remedy for respiratory disease
US4900730A (en) *	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
ATE23272T1 (de) *	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
SE438261B (sv) *	1981-07-08	1985-04-15	Draco Ab	Anvendning i dosinhalator av ett perforerat membran
US5260306A (en)	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4959358A (en) *	1983-06-06	1990-09-25	Beth Israel Hospital Assn.	Drug administration
US4548922A (en) *	1983-06-06	1985-10-22	Beth Israel Hospital	Drug administration
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration
US4963367A (en)	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
US5288498A (en)	1985-05-01	1994-02-22	University Of Utah Research Foundation	Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
JPS61267528A (ja) *	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) *	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
IL78425A (en)	1985-04-15	1991-05-12	Lilly Co Eli	Intranasal formulation containing insulin
US5122127A (en)	1985-05-01	1992-06-16	University Of Utah	Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
WO1986006959A1 (en)	1985-05-22	1986-12-04	Liposome Technology, Inc.	Liposome inhalation method and system
US4847298A (en)	1985-08-16	1989-07-11	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
IL77186A0 (en) *	1985-11-29	1986-04-29	Touitou Elka	Pharmaceutical insulin composition
SE453566B (sv) *	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
JPS632932A (ja)	1986-06-23	1988-01-07	Teijin Ltd	経鼻投与用粉末状組成物
EP0257915B1 (en)	1986-08-11	1993-03-10	Innovata Biomed Limited	Pharmaceutical formulations comprising microcapsules
US5179079A (en) *	1986-12-16	1993-01-12	Novo Nordisk A/S	Nasal formulation and intranasal administration therewith
NZ222907A (en) *	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
GB8712176D0 (en) *	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
JPH01117825A (ja)	1987-10-28	1989-05-10	Sanwa Kagaku Kenkyusho Co Ltd	鼻くう、副鼻くう投与用製剤及びその使用方法並びにその形状及び使用器具
EP0360340A1 (en) *	1988-09-19	1990-03-28	Akzo N.V.	Composition for nasal administration containing a peptide
US5997856A (en) *	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
SE8803935L (sv) *	1988-10-31	1990-05-01	Kabivitrum Ab	Laekemedelskomposition
US5006343A (en)	1988-12-29	1991-04-09	Benson Bradley J	Pulmonary administration of pharmaceutically active substances
GB8900267D0 (en)	1989-01-06	1989-03-08	Riker Laboratories Inc	Narcotic analgesic formulations and apparatus containing same
US4994439A (en)	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
US5011678A (en)	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
AU639228B2 (en)	1989-02-17	1993-07-22	Transave, Inc.	Lipid excipient for nasal delivery and topical application
IT8920486A0 (it)	1989-05-12	1989-05-12	Isf Spa	Composizioni farmaceutiche.
US5176132A (en)	1989-05-31	1993-01-05	Fisons Plc	Medicament inhalation device and formulation
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
US5258185A (en) *	1989-08-23	1993-11-02	Bauer Kurt H	Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB8921222D0 (en)	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5376386A (en)	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
GB9001635D0 (en)	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5118494A (en)	1990-03-23	1992-06-02	Minnesota Mining And Manufacturing Company	Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (ja) *	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
US5192548A (en) *	1990-04-30	1993-03-09	Riker Laboratoires, Inc.	Device
AU7908791A (en)	1990-05-08	1991-11-27	Liposome Technology, Inc.	Direct spray-dried drug/lipid powder composition
ES2117642T3 (es)	1990-05-10	1998-08-16	Bechgaard Int Res	Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
JPH0441421A (ja)	1990-06-07	1992-02-12	Taisho Pharmaceut Co Ltd	肺吸収組成物
JPH04149126A (ja)	1990-10-09	1992-05-22	Mitsubishi Kasei Corp	経粘膜投与用医薬組成物
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
GB9024365D0 (en)	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
JP3507486B2 (ja)	1991-03-15	2004-03-15	アムジエン・インコーポレーテツド	顆粒球コロニー刺激因子の肺内投与
US5320094A (en)	1992-01-10	1994-06-14	The Johns Hopkins University	Method of administering insulin
CA2127877A1 (en) *	1992-01-21	1993-07-22	Robert M. Platz	Improved process for preparing micronized polypeptide drugs
EP0566135A1 (en) *	1992-04-17	1993-10-20	Takeda Chemical Industries, Ltd.	Transmucosal composition comprising a peptide and a cytidine derivative
DE69332240T2 (de)	1992-06-12	2003-04-10	Teijin Ltd., Osaka	Ultrafeines pulver zur inhalation und dessen herstellung
US5376359A (en) *	1992-07-07	1994-12-27	Glaxo, Inc.	Method of stabilizing aerosol formulations
WO1994007514A1 (en) *	1992-09-29	1994-04-14	Inhale Therapeutic Systems	Pulmonary delivery of active fragments of parathyroid hormone
ES2154673T3 (es) *	1993-01-29	2001-04-16	Aradigm Corp	Suministro intrapulmonar de hormonas.
US5364838A (en)	1993-01-29	1994-11-15	Miris Medical Corporation	Method of administration of insulin
BE1006873A6 (nl)	1993-03-26	1995-01-10	Merkus Franciscus W H M	Toedieningsformulering voor nasale insuline toediening.
DE69413528T2 (de)	1993-04-06	1999-05-06	Minnesota Mining And Mfg. Co., Saint Paul, Minn.	Vorrichtung zum deagglomerieren für trockenpulverinhalatoren
US5747445A (en)	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
US5661130A (en)	1993-06-24	1997-08-26	The Uab Research Foundation	Absorption enhancers for drug administration
GB9314614D0 (en)	1993-07-14	1993-08-25	Minnesota Mining & Mfg	Dry powder inhalers
US5514670A (en)	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
CZ295827B6 (cs) *	1994-03-07	2005-11-16	Nektar Therapeutics	Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US5451569A (en)	1994-04-19	1995-09-19	Hong Kong University Of Science And Technology R & D Corporation Limited	Pulmonary drug delivery system
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations

1994
- 1994-06-20 TW TW083105540A patent/TW402506B/zh not_active IP Right Cessation
- 1994-06-21 IS IS4178A patent/IS1768B/is unknown
- 1994-06-22 IL IL11008494A patent/IL110084A/xx not_active IP Right Cessation
- 1994-06-22 EG EG36694A patent/EG20599A/xx active
- 1994-06-23 PL PL94312205A patent/PL178403B1/pl not_active IP Right Cessation
- 1994-06-23 KR KR1019950705904A patent/KR100372673B1/ko not_active Expired - Fee Related
- 1994-06-23 ES ES94919960T patent/ES2138087T3/es not_active Expired - Lifetime
- 1994-06-23 BR BR9406907A patent/BR9406907A/pt not_active Application Discontinuation
- 1994-06-23 RU RU96103636A patent/RU2148398C1/ru not_active IP Right Cessation
- 1994-06-23 SK SK1601-95A patent/SK283145B6/sk not_active IP Right Cessation
- 1994-06-23 NZ NZ268137A patent/NZ268137A/en not_active IP Right Cessation
- 1994-06-23 DE DE69420412T patent/DE69420412T2/de not_active Expired - Lifetime
- 1994-06-23 DK DK94919960T patent/DK0706382T3/da active
- 1994-06-23 MX MX9404761A patent/MX9404761A/es unknown
- 1994-06-23 UA UA95125417A patent/UA49794C2/uk unknown
- 1994-06-23 AU AU70901/94A patent/AU692780B2/en not_active Ceased
- 1994-06-23 MY MYPI94001630A patent/MY112098A/en unknown
- 1994-06-23 CN CN94193190A patent/CN1110301C/zh not_active Expired - Fee Related
- 1994-06-23 US US08265372 patent/US5518998C1/en not_active Expired - Lifetime
- 1994-06-23 JP JP50273695A patent/JP3874789B2/ja not_active Expired - Fee Related
- 1994-06-23 AT AT94919960T patent/ATE183920T1/de active
- 1994-06-23 CA CA002166108A patent/CA2166108C/en not_active Expired - Fee Related
- 1994-06-23 HU HU9503659A patent/HU228129B1/hu not_active IP Right Cessation
- 1994-06-23 EP EP94919960A patent/EP0706382B1/en not_active Expired - Lifetime
- 1994-06-23 CZ CZ19953428A patent/CZ287314B6/cs not_active IP Right Cessation
- 1994-06-23 WO PCT/SE1994/000633 patent/WO1995000127A1/en active IP Right Grant
- 1994-06-27 SA SA94150030A patent/SA94150030B1/ar unknown
- 1994-11-23 EE EE9400429A patent/EE03221B1/xx not_active IP Right Cessation
1995
- 1995-06-06 US US08/471,488 patent/US5658878A/en not_active Expired - Lifetime
- 1995-12-21 NO NO19955226A patent/NO313657B1/no not_active IP Right Cessation
- 1995-12-22 FI FI956227A patent/FI111688B/fi not_active IP Right Cessation
1997
- 1997-08-06 US US08/906,825 patent/US6306440B1/en not_active Expired - Fee Related
1998
- 1998-08-29 HK HK98110295A patent/HK1009584A1/xx not_active IP Right Cessation
1999
- 1999-11-29 GR GR990403067T patent/GR3031974T3/el unknown
2005
- 2005-11-09 JP JP2005325056A patent/JP4294635B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL110084A (en)	1999-07-14
CA2166108A1 (en)	1995-01-05
GR3031974T3 (en)	2000-03-31
MY112098A (en)	2001-04-30
EP0706382B1 (en)	1999-09-01
SA94150030B1 (ar)	2006-04-04
UA49794C2 (uk)	2002-10-15
HK1009584A1 (en)	1999-06-04
AU692780B2 (en)	1998-06-18
CZ342895A3 (en)	1996-05-15
JP2006089496A (ja)	2006-04-06
BR9406907A (pt)	1996-04-02
SK160195A3 (en)	1997-02-05
CN1110301C (zh)	2003-06-04
HUT75065A (en)	1997-03-28
WO1995000127A1 (en)	1995-01-05
US5518998C1 (en)	2001-02-13
TW402506B (en)	2000-08-21
EP0706382A1 (en)	1996-04-17
CN1129904A (zh)	1996-08-28
US6306440B1 (en)	2001-10-23
ES2138087T3 (es)	2000-01-01
NO955226L (no)	1996-02-15
JP3874789B2 (ja)	2007-01-31
HU228129B1 (en)	2012-12-28
NO955226D0 (no)	1995-12-21
NZ268137A (en)	1997-10-24
DE69420412D1 (de)	1999-10-07
JPH08512027A (ja)	1996-12-17
DK0706382T3 (da)	2000-03-13
AU7090194A (en)	1995-01-17
PL312205A1 (en)	1996-04-01
IS1768B (is)	2001-05-02
FI956227A0 (fi)	1995-12-22
JP4294635B2 (ja)	2009-07-15
US5658878A (en)	1997-08-19
PL178403B1 (pl)	2000-04-28
EE03221B1 (et)	1999-10-15
MX9404761A (es)	1995-01-31
IS4178A (is)	1994-12-25
EG20599A (en)	1999-09-30
KR100372673B1 (ko)	2003-05-12
HU9503659D0 (en)	1996-02-28
US5518998A (en)	1996-05-21
FI111688B (fi)	2003-09-15
CA2166108C (en)	2008-10-21
FI956227L (fi)	1995-12-22
CZ287314B6 (en)	2000-10-11
IL110084A0 (en)	1994-10-07
SK283145B6 (sk)	2003-03-04
RU2148398C1 (ru)	2000-05-10
ATE183920T1 (de)	1999-09-15
DE69420412T2 (de)	2000-04-13

Publication	Publication Date	Title
NO313657B1 (no)	2002-11-11	Terapautisk preparat for inhalering, fremgangsmåte for fremstilling av dette, anvendelse av en forsterker, ogtörrpulverinhalator
US5747445A (en)	1998-05-05	Therapeutic preparation for inhalation
US6165976A (en)	2000-12-26	Therapeutic preparation for inhalation
US5506203A (en)	1996-04-09	Systemic administration of a therapeutic preparation
US6846801B1 (en)	2005-01-25	Systemic administration of a therapeutic preparation
US5952008A (en)	1999-09-14	Processes for preparing compositions for inhalation
US6004574A (en)	1999-12-21	Powder formulations containing melezitose as a diluent
US6436902B1 (en)	2002-08-20	Therapeutic preparations for inhalation
US20030211972A1 (en)	2003-11-13	Systemic administration of a therapeutic preparation
US20010025037A1 (en)	2001-09-27	Systemic administration of a therapeutic preparation
LT3445B (en)	1995-10-25	Therapeutic preparation for inhalation
NZ328475A (en)	2001-04-27	A pharmaceutical composition containing a polypeptide up to 40 kD and an enhancer for systemic delivery by inhalation

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees